Abstract
1. In a prospective controlled trial in patients undergoing hip operations, six out of thirty-three patients receiving prophylactic Dextran 70, and five out of thirty-three patients receiving only dextrose, were shown by ascending phlebography to have ilio-femoral thrombosis. Oedema was the only consistent clinical finding. 2. This study does not therefore support the conclusion of other reports that Dextran 70 is of value in preventing ilio-femoral thrombosis after operations on the hip joint. 3. It is suggested that patients needing operation on the hip joint are especially prone to major vein thrombosis and it may be that higher dosage of Dextran 70 is indicated. 4. This controlled investigation of sixty-six patients, now submitted as a preliminary report, is continuing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Bone and Joint Surgery. British volume
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
